By Josh Beckerman
Shares of Sonnet BioTherapeutics Holdings Inc. were up 8% to $1.40 after it announced a clinical collaboration agreement with Roche Holding AG.
In Sonnet's first combination clinical study, Sonnet's SON-1010 and Roche's atezolizumab will be evaluated in patients with platinum-resistant ovarian cancer.
Sonnet expects to begin the study in the second quarter.
In October, Sonnet announced a collaboration agreement with Janssen Biotech Inc., which is part of Johnson & Johnson. It said SON-1010, SON-1210 and SON-1410 would be evaluated in combination with certain Janssen proprietary cell therapy assets.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
01-09-23 1325ET